Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
03
03
2021
accepted:
21
04
2021
entrez:
2
12
2021
pubmed:
3
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) have shown very promising results in the management of patients with inoperable or metastatic cutaneous squamous cell carcinoma (cSCC). However, ICI can cause a range of immune-related adverse events (irAEs) affecting a multitude of organs including skin, gastrointestinal tract, endocrine system, heart, lung, kidneys and the nervous system. In principle, clinical management irAEs does not change significantly with respect to the kind of cancer treated with ICI. However, advanced cSCC typically occurs in a clinically challenging patient population typically presenting with advanced age and/or significant comorbidities such as immunosuppression due to haematological malignancies and their respective treatment. Moreover, many patients with advanced cSCC are organ transplant patients taking immunosuppressants. As a consequence use of ICI per se and management of ICI-induced irAEs generates more complexity and difficulties in patients with cSCC compared to other entities. Here, we provide a brief review on the management of anti-programmed cell death protein 1-induced irAEs in patients with cSCC focusing on the characteristic clinical challenges present in this population.
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-28Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Gambichler T, Susok L. Fortgeschrittene basalzell- und plattenepithelkarzinome der haut. Best Pract Onkol 2019; 6: 262-271.
Migden MR, Khushalani NI, Chang ALS et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020; 21: 294-305.
Maubec E, Boubaya M, Petrow P et al. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol 2020; 38: 3051-3061.
Wessely A, Steeb T, Leiter U, Garbe C, Berking C, Heppt MV. Immune checkpoint blockade in advanced cutaneous squamous cell carcinoma: what do we currently know in 2020? Int J Mol Sci 2020; 21: 9300.
Leiter U, Loquai C, Reinhardt L et al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer 2020; 8: e000897.
Perier-Muzet M, Gatt E, Péron J et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol 2018; 154: 82-87.
Yeung SJ, Qdaisat A, Chaftari P et al. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open 2020; 1: 1637-1659.
Song P, Zhang D, Cui X, Zhang L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer 2020; 11: 2406-2430.
Morgado M, Plácido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines (Basel) 2020; 8: 575.
Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-148.
Brahmer JR, Lacchetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768.
Londoño MC, Reig M; RETOINMUNO Multidisciplinary Group. Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors. Cancers (Basel) 2020; 12: 3446.
Hanna GJ, Ruiz ES, LeBoeuf NR et al. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer 2020; 123: 1535-1542.
In GK, Vaidya P, Filkins A et al. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol 2021; 147: 1803-1811.
Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist 2021; 26: 133-138.
Caillet P, Laurent M, Bastuji-Garin S et al. Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment. Clin Interv Aging 2014; 29: 1645-1660.
Mohile SG, Epstein RM, Hurria A et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the national cancer institute community oncology research program. JAMA Oncol 2020; 6: 196-204.
Gambichler T, Reuther J, Scheel CH, Susok L, Kern P, Becker JC. Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection. Cancers (Basel) 2020; 12: 3383.
Saponara M, Pala L, Conforti F et al. Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Ther Adv Med Oncol 2020; 20: 1758835920977002.
Habre M, Habre SB, Kourie HR. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy 2016; 8: 1437-1446.